The challenge:<\/em><\/strong> Their procurement cycles are long, their compliance requirements are strict, and their IT teams will not seriously consider any vendor who cannot speak fluently about how their product fits into an SAP-centric stack.<\/p>\n Not all SAP environments create the same sales opportunities. Each module aligns with different stakeholders, budgets, and enterprise priorities.<\/p>\n Operational backbone for finance, procurement, and manufacturing across pharma and biotech.<\/p>\n Supports compliance, CAPA workflows, and validated manufacturing environments.<\/p>\n Handles serialization and compliance like DSCSA & EU FMD.<\/p>\n Supports demand forecasting and global supply planning.<\/p>\n Manages clinical trial logistics and supply chain.<\/p>\n Innovation layer for AI, integration, and Clean Core architecture.<\/p>\n For vendors selling into pharma and biotech, understanding where your solution fits within these SAP environments is essential to reaching the right buyers, aligning with active budgets, and accelerating enterprise sales cycles.<\/p>\n<\/div>\n<\/section>\n <\/p>\n A common mistake vendors make is treating pharma and biotech as the same buyer. They are not.<\/p>\n The difference shows up in how SAP is deployed, how mature the environment is, and how procurement decisions are made across company types.<\/p>\n Large pharmaceutical companies run SAP across the full enterprise, from manufacturing and supply chain to quality, finance, and R&D. These environments are often deeply customized, globally integrated, and supported by large internal IT teams.<\/p>\n What this means for vendors:<\/em><\/strong> Longer sales cycles, larger budgets, more stakeholders, and higher barriers to entry, but substantial enterprise-scale opportunities.<\/p>\n Mid-sized pharmaceutical firms typically use SAP across core functions like finance, procurement, and manufacturing while relying more selectively on specialized platforms elsewhere.<\/p>\n What this means for vendors:<\/em><\/strong> Faster procurement, shorter migration timelines, and more agile buying processes with lower enterprise complexity.<\/p>\n Commercial-stage biotech organizations often operate SAP environments similar to larger pharma companies, particularly as manufacturing and commercialization expand.<\/p>\n What this means for vendors:<\/em><\/strong> Growing budgets, increasing operational sophistication, and expanding enterprise software demand.<\/p>\n Biotech firms approaching Phase 3 or commercial launch often implement SAP when manufacturing scale and regulatory demands accelerate.<\/p>\n What this means for vendors:<\/em><\/strong> High-value timing for infrastructure, implementation, and operational expansion solutions.<\/p>\n Smaller biotech organizations often maintain leaner technology stacks and may not yet operate within SAP environments.<\/p>\n What this means for vendors:<\/em><\/strong> Limited immediate SAP opportunity, but valuable long-term pipeline potential.<\/p>\n If you sell into life sciences, segmenting by company stage is often more effective than broad industry classification alone. SAP deployment maturity directly shapes budgets, buyer complexity, and outbound strategy.<\/p>\n <\/p>\n Active budget in pharma SAP environments is concentrated around a handful of major transformation, compliance, and modernization cycles. Vendors aligned with these priorities are more likely to reach active buyers.<\/p>\n <\/p>\n <\/p>\n The largest SAP investment cycle as enterprises move away from ECC before 2027 deadlines. RISE with SAP is driving major spending across migration, ERP extensions, and integration platforms.<\/p>\n<\/div>\n <\/p>\n Post-compliance investments are rising as companies optimize rushed serialization systems, improve packaging integrations, and enhance track-and-trace performance.<\/p>\n<\/div>\n <\/p>\n Growing complexity across cloud and on-premise systems is driving demand for governance, validation, and tools that simplify hybrid SAP environments.<\/p>\n<\/div>\n <\/p>\n SAP advancements are accelerating AI adoption in quality, supply chain, and R&D, driving investments in predictive intelligence and automation.<\/p>\n<\/div>\n <\/p>\n Integration between Veeva and SAP ecosystems continues to drive enterprise investment in data flow, compliance, and workflow alignment.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n Most vendors selling into pharma SAP environments fail in the same predictable ways.<\/p>\n They send generic SAP-themed outreach to anyone with “SAP” in their LinkedIn profile, ignoring that pharma SAP buyers expect industry-specific knowledge. They lead with their product instead of the regulatory or operational pain it solves. They pitch to titles that do not own the budget for the specific module their product touches. And they run unverified contact lists that bounce off pharma email security and damage their sender reputation.<\/p>\n The fix is not complicated. Identify which SAP module your product actually integrates with or extends. Identify the role that owns the buying decision for that module (the table earlier in this article gives you a starting point).<\/p>\n Build a verified contact list scoped to those roles at companies running SAP in life sciences. Then send outreach that speaks the language of the module, not generic SAP marketing.<\/p>\n If you need a starting point on the data layer, our SAP Life Sciences Users List<\/a> tracks 1,825+ companies and 8,200+ verified contacts across pharmaceutical, biotech, and healthcare organizations using SAP. The list is segmented by SAP module, company size, geography, and functional role, which is exactly the level of targeting this market requires.<\/p>\n S\/4HANA (core ERP), Quality Management (QM), Advanced Track and Trace for Pharmaceuticals (ATTP), Integrated Business Planning (IBP), and Clinical Supply Management. Most large pharma companies run all five. Biotechs typically start with S\/4HANA and add modules as they scale.<\/p>\n Yes. Over 80% of the top 20 pharma companies run SAP, and SAP itself reports that 95% of global life sciences companies use its solutions. Oracle and NetSuite are competitive in mid-market biotech, but SAP remains the standard for established pharma.<\/p>\n A full S\/4HANA migration in big pharma typically runs 18 to 36 months because of the validation, regulatory documentation, and integration work required. Mid-market pharma deployments often complete in 9 to 18 months. Biotechs adopting SAP for the first time are usually in the 6 to 12-month range.<\/p>\n ECC to S\/4HANA migration is the largest single budget driver because SAP ECC mainstream maintenance ends December 31, 2027. DSCSA serialization remediation, cloud governance, and AI pilots are the next three biggest spending waves.<\/p>\n It depends on the module. Core ERP and infrastructure decisions sit with the CIO and VP of IT. Quality and compliance tools sit with the Head of Quality. Serialization and supply chain sit with the VP of Supply Chain. Clinical systems sit with the Head of Clinical Operations. Vendors who target the right title for their product see meaningfully higher response rates.<\/p>\n Span Global Services is a Champions Group company providing verified B2B data, lead generation, and demand generation services to over 6,000 clients globally. With deep specialization in technology install base intelligence, including life sciences SAP environments, SGS helps vendors reach the right buyers inside complex regulated industries. Learn more<\/a> or explore our resources<\/a>.<\/p>\n If you sell into SAP-using pharma and biotech companies:<\/strong> Browse the SAP Life Sciences Users List<\/a> for verified contacts segmented by SAP module, company size, and role.<\/p>\n If you need broader pharma industry coverage,<\/strong> Explore the Pharmaceutical Industry Email List<\/a> to reach decision-makers across the wider life sciences market.<\/p>\nThe Six SAP Areas That Actually Matter in Life Sciences<\/h2>\n
SAP S\/4HANA (Core ERP)<\/h3>\n
\n
SAP Quality Management (QM)<\/h3>\n
\n
SAP ATTP<\/h3>\n
\n
SAP IBP<\/h3>\n
\n
SAP Clinical Supply<\/h3>\n
\n
SAP BTP & AI<\/h3>\n
\n
<\/h2>\n
How Pharma and Biotech Differ in Their SAP Usage<\/h2>\n
![\"Life](\"https:\/\/www.spanglobalservices.com\/blog\/wp-content\/uploads\/2026\/05\/Life-Science-Market-Segmentation-Strategy-scaled-e1777971073751-1024x560.png\")
<\/a><\/p>\nBig Pharma<\/h3>\n
Mid-Market Pharma<\/h3>\n
Established Biotech<\/h3>\n
Mid-Stage Biotech<\/h3>\n
Early-Stage Biotech<\/h3>\n
What Is Driving Active Budgets in 2026<\/h2>\n
ECC to S\/4HANA Migration<\/h3>\n
DSCSA Remediation & Serialization<\/h3>\n
Cloud Governance & Hybrid SAP<\/h3>\n
AI & Predictive Analytics Expansion<\/h3>\n
Veeva – SAP Integration Demand<\/h3>\n
<\/h2>\n
Where Your Outbound Goes Wrong<\/h2>\n
Frequently Asked Questions<\/h2>\n
Which SAP Modules Are Most Common in Pharma and Biotech?<\/h3>\n
Is SAP Still the Default ERP for Pharma in 2026?<\/h3>\n
How Long Do SAP Implementations Take in Life Sciences?<\/h3>\n
What Is the Biggest 2026 Spending Driver in Pharma SAP Environments?<\/h3>\n
Who Owns the Buying Decision for SAP-Adjacent Products in Pharma?<\/h3>\n
About Span Global Services<\/h2>\n
Continue Reading<\/h2>\n